Abstract Library

#4294 Measuring quality of life in patients receiving radionuclide therapy using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ- C30) and Gastro-intestinal NET (GINET) 21

Introduction: Neuroendocrine tumours over express somatostatin receptors on the cell surface. These receptors can be targeted by radiation via Peptide Receptor Radionuclide Therapy (PRRT). NETTER 01 trial demonstrated excellent results in progression-free survival. Scottish National service commenced April 2019 at Beatson West of Scotland Cancer Centre. Service Level Agreement to submit multiple metrics including Patient Reported Outcome Measures (PROM) and Patient Reported Experience Measures (PREM). EORTC QLQ 30 and GI NET 21 validated research tools which are used to measure outcomes.

Conference:

Presenting Author: Wotherspoon I

Authors: Wotherspoon I,

Keywords: EORTC 30 QLQ with the GINET 21 module,

#4069 Impact of nutritional status in the quality of life (QoL) of patients with advanced gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) in Spain: NUTRIGETNE Study

Introduction: Prevalence of malnutrition and sarcopenia is high among patients with advanced GEP-NENs and may significantly decrease response to therapy and impair QoL.

Conference:

Presenting Author:

Authors: Del Olmo-García M, Garcia-Carbonero R, Hernando J, Pérez-Wert P, Suarez Gutiérrez L,

Keywords: nutritional status, Gastroenteropancreatic, Neuroendocrine neoplasm, Sarcopenia, Malnutrition,

#3777 The value of the Patient Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE) in patients with neuroendocrine tumors (NET) treated with 177Lutetium-DOTATATE (177Lu)

Introduction: The correlation between clinical benefit and toxicity is an unmet need in daily clinical practice. PRO-CTCAE is a questionnaire that allows subjective and detailed symptom reporting directly from patients. This prospective, multicentre study will apply PRO-CTCAE in a cohort of consecutive adult patients with metastatic NET on treatment with 177Lu.

Conference:

Presenting Author: Hernando J

Authors: Carmona Alonso A, Hernando Cubero J, Garcia Alvarez A, Roca-Herrera M, Garcia Burillo A,

Keywords: TNE, 177Lu, PRO-CTCAE,

#3578 Optimal PLAnning of treatment and research of Neuroendocrine Tumors (NETs) in Australia: The PLANET registry and patient reported outcomes via PLANET App

Introduction: Neuroendocrine Neoplasms (NENs) are challenging to diagnose and manage due to their varied behaviour. Despite usually having an indolent course, they are often metastatic at diagnosis and can be associated with significant long-term morbidity and impaired quality-of-life (QOL). The PLANET registry was established to collate clinical data from tertiary NET centres and integrate these with real-time patient reported outcomes (PROs) enabled by the smartphone-based PLANET App.

Conference:

Presenting Author: Leyden S

Authors: Leyden S, Cummins M, Pavlakis N, Ransom D, Price T,

Keywords: data, PROMS, PROs, QOLs, real-world data,

#3552 Fatigue and quality of life in patients with neuroendocrine neoplasia

Introduction: Neuroendocrine Neoplasms (NEN) are rare tumors and health related quality of life (HRQoL) may be modulated by the disease and the accompanying carcinoid syndrome seen especially in small intestinal NENs. Further, cancer related fatigue is one of the most common side effects of cancer and its treatments and may persist for years after treatment completion.

Conference:

Presenting Author: Hummelshøj N

Authors: Hummelshøj N, Grønbæk H, Bager P, Tabaksblat E, Dam G,

Keywords: Neuroendocrine, HRQoL, Fatigue, Patient reported outcome, Carcinoid syndrome,